DNA Oyj financials
DNA Oyj
7437003Y73DAKAXYJV21 | Line item | 2021 | 2020 | 2019 |
|---|---|---|---|
| Income statement | |||
| Revenue | €956.0M | €932.3M | — |
| Employee benefits expense | €116.6M | €112.6M | — |
| Raw materials & consumables used | €379.4M | €385.3M | — |
| Depreciation & amortisation | €204.4M | €181.2M | — |
| Operating profit (EBIT) | €154.2M | €151.4M | — |
| Finance costs | €7.2M | €8.5M | — |
| Profit before tax | €147.3M | €143.4M | — |
| Income tax expense | €29.6M | €28.6M | — |
| Profit for the year | €117.7M | €114.8M | — |
| — attributable to owners | €117.7M | €114.8M | — |
| Total comprehensive income | €117.4M | €115.1M | — |
| Cash flow statement | |||
| Net cash from operating activities | €337.8M | €295.9M | — |
| Net cash from investing activities | -€164.1M | -€190.6M | — |
| Net cash from financing activities | -€170.6M | -€115.1M | — |
| Proceeds from borrowings | €95.0M | €77.2M | — |
| Repayments of borrowings | €223.1M | €168.0M | — |
| Lease liability payments | €42.4M | €24.2M | — |
| Balance sheet | |||
| Total assets | €1.65B | €1.61B | €1.44B |
| Non-current assets | €1.25B | €1.26B | €1.11B |
| Property, plant & equipment | €469.7M | €461.7M | €427.4M |
| Right-of-use assets | €232.6M | €249.1M | €135.5M |
| Intangible assets & goodwill | €338.7M | €338.7M | €338.7M |
| Current assets | €396.1M | €352.5M | €329.5M |
| Inventories | €38.2M | €33.7M | €34.3M |
| Trade & other receivables | €311.7M | €272.8M | €241.9M |
| Cash & equivalents | €10.8M | €7.6M | €17.4M |
| Total equity | €769.4M | €657.2M | €551.1M |
| Non-current liabilities | €538.9M | €588.3M | €602.0M |
| Lease liabilities (non-current) | €144.7M | €161.5M | €77.3M |
| Current liabilities | €341.3M | €366.3M | €288.3M |
| Lease liabilities (current) | €43.9M | €48.0M | €23.0M |
| Trade & other payables | €284.4M | €254.4M | €230.9M |
| Deferred tax liabilities | €52.7M | €44.1M | €36.9M |
| Derived metrics | |||
| Operating margin | 16.1% | 16.2% | — |
| Net margin | 12.3% | 12.3% | — |
| Return on equity | 15.3% | 17.5% | — |
| Cash conversion ratio | 2.87× | 2.58× | — |
| Other reported items | |||
| Adjustments For Decrease Increase In Inventories | -€4.5M | €579.0K | — |
| Adjustments For Decrease Increase In Trade and Other Receivables | -€20.9M | -€1.0M | — |
| Adjustments For Depreciation and Amortisation Expense | €204.4M | €181.2M | — |
| Adjustments For Finance Income Cost | -€6.9M | -€8.0M | — |
| Adjustments For Income Tax Expense | €29.6M | €28.6M | — |
| Adjustments For Increase Decrease In Trade and Other Payables | €27.7M | -€5.7M | — |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | -€431.0K | -€2.2M | — |
| Adjustments For Provisions | €346.0K | -€652.0K | — |
| Adjustments For Reconcile Profit Loss | €240.8M | €215.0M | — |
| Basic and Diluted Earnings Loss Per Share From Continuing Operations | €0.89 | €0.87 | — |
| Comprehensive Income Attributable To Owners of Parent | €117.4M | €115.1M | — |
| Current Contract Assets | €1.3M | €6.2M | €8.8M |
| Current Contract Liabilities | €2.9M | €3.3M | €4.7M |
| Current Prepayments and Current Accrued Income | €23.8M | €28.4M | €24.9M |
| Current Tax Assets Current | €10.3M | €3.9M | €2.2M |
| Current Tax Liabilities Current | €9.8M | €381.0K | €388.0K |
| Deferred Tax Assets | €7.0M | €7.6M | €7.2M |
| Dividends Received Classified As Operating Activities | €36.0K | €36.0K | — |
| Equity and Liabilities | €1.65B | €1.61B | €1.44B |
| Finance Income | €304.0K | €530.0K | — |
| Income Taxes Paid Refund Classified As Operating Activities | €15.9M | €21.0M | — |
| Increase Decrease In Cash and Cash Equivalents | €3.2M | -€9.8M | — |
| Increase Decrease In Working Capital | -€2.3M | €6.1M | — |
| Increase Decrease Through Sharebased Payment Transactions | €300.0K | €1.5M | — |
| Increase Decrease Through Transactions With Owners | -€5.2M | -€9.0M | — |
| Intangible Assets Other Than Goodwill | €127.7M | €130.1M | €137.3M |
| Interest Paid Classified As Operating Activities | €5.3M | €5.5M | — |
| Interest Received Classified As Operating Activities | €272.0K | €471.0K | — |
| Investments In Subsidiaries Joint Ventures and Associates | €1.2M | €1.2M | €1.2M |
| Issued Capital | €72.7M | €72.7M | €72.7M |
| Noncurrent Provisions For Employee Benefits | €1.5M | €1.2M | €1.5M |
| Noncurrent Receivables | €76.5M | €70.7M | €64.5M |
| Other Adjustments For Noncash Items | -€16.0K | -€12.0K | — |
| Other Comprehensive Income | -€310.0K | €290.0K | — |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | -€310.0K | €290.0K | — |
| Other Current Financial Liabilities | €0 | €60.0M | €28.8M |
| Other Expense By Nature | €101.4M | €101.8M | — |
| Other Inflows Outflows of Cash Classified As Investing Activities | -€91.0K | -€1.0K | — |
| Other Inflows Outflows of Cash Classified As Operating Activities | -€2.2M | -€1.7M | — |
| Other Longterm Provisions | €14.1M | €11.8M | €5.0M |
| Other Noncurrent Financial Assets | €111.0K | €111.0K | €110.0K |
| Other Noncurrent Financial Liabilities | €313.9M | €357.6M | €472.4M |
| Other Noncurrent Nonfinancial Liabilities | €12.0M | €12.1M | €8.9M |
| Other Shortterm Provisions | €326.0K | €208.0K | €470.0K |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | €16.0K | €12.0K | — |
| Treasury Shares | €1.7M | €1.7M | €1.7M |
Every line item above is a fact tagged in DNA Oyj's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.